Skip to content
Inciteful Med
Resources About us Ask a Question

Why Does Lenalidomide Treatment Require a Blood Thinner?

Published: | Updated:

Lenalidomide (Revlimid) increases the risk of blood clots, especially when taken with dexamethasone for multiple myeloma. To protect you, doctors prescribe a daily preventative medication, ranging from a standard aspirin to prescription blood thinners, based on your personal risk score.

Key Takeaways

  • • Lenalidomide alters blood chemistry and significantly increases the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).
  • • The risk of developing a blood clot is highest during the first six months of treatment, particularly when combined with dexamethasone.
  • • Doctors use specialized scoring systems like IMPEDE VTE or SAVED to determine if you need a daily aspirin or a stronger prescription blood thinner.
  • • Never stop taking your prescribed blood thinner or aspirin without consulting your oncology team, even if you feel fine.
  • • Seek emergency medical help immediately if you experience leg swelling, sudden shortness of breath, or sharp chest pain.

If you are taking lenalidomide (Revlimid) for multiple myeloma, your doctor will also prescribe a preventative medication, such as a daily aspirin or a prescription blood thinner [1][2]. This is because lenalidomide, while highly effective against myeloma, comes with a known and manageable side effect: it increases your risk of developing a venous thromboembolism (VTE), which is a blood clot in the deep veins of your legs (a deep vein thrombosis, or DVT) or your lungs (a pulmonary embolism, or PE) [3][4]. Taking a blood thinner is a standard, required step to safely protect you from these clots during your cancer treatment [5].

Why Does Lenalidomide Cause Blood Clots?

Lenalidomide is an immunomodulatory drug (IMiD). It causes changes in your blood by making your platelets (the cells responsible for clotting) more responsive and altering specific chemical signals in your bloodstream [6][7].

This risk of clotting is especially high when lenalidomide is combined with corticosteroids like dexamethasone [8][9]. Because the combination of Revlimid and dexamethasone is a standard treatment for multiple myeloma, almost all patients on this regimen will experience this “hypercoagulable state” (meaning the blood clots too easily) [7].

The risk of developing a blood clot is highest during the first six months of your treatment [2][10]. This is often because the amount of myeloma in your body is highest at the beginning, adding to the clot risk [10]. However, never stop taking your preventative blood thinner or aspirin without consulting your care team, even after six months. Many patients need to remain on these medications for as long as they take lenalidomide [11].

How Your Care Team Chooses Your Medication

Not every patient needs the strongest blood thinner. Doctors use specialized scoring systems—such as the IMPEDE VTE or SAVED scores—to calculate your personal risk [12][13].

To calculate your score, your doctor will evaluate several factors, including:

  • Your body mass index (BMI) [12]
  • Any personal or family history of blood clots [12]
  • Whether you have had recent surgeries or bone fractures [13][12]
  • If you have a central venous catheter (a port or central line) [12]
  • Whether you are taking dexamethasone (which automatically applies to most lenalidomide patients) [14]

Based on your score, your doctor will prescribe one of the following:

  • For lower-risk patients: A daily dose of standard or baby aspirin is often enough to prevent clots [15][16].
  • For higher-risk patients: You may need a stronger prescription medication [17][18]. These include direct oral anticoagulants (DOACs) like apixaban (Eliquis) or rivaroxaban (Xarelto), or low-molecular-weight heparin (LMWH), which is a daily injection like enoxaparin (Lovenox). Recent evidence suggests DOACs are highly effective at preventing clots in newly diagnosed patients [17][1].

Note on Kidney Function: Many multiple myeloma patients have kidney involvement. If this applies to you, your doctor may adjust your medication dose or choose a specific blood thinner that is safer for your kidneys [17].

Taking these preventative medications is generally considered safe, with a very low risk of serious bleeding complications [19].

What You Can Do

In addition to taking your medication, there are lifestyle factors you can control to further lower your risk of blood clots [11][10]:

  • Stay well-hydrated throughout the day.
  • Avoid prolonged immobility (e.g., getting up to walk regularly during long flights or car rides).
  • Remain as physically active as your doctor safely allows.

Even with preventative measures, you should know the universal warning signs of a blood clot [3][4]. Seek emergency medical attention if you experience:

  • Swelling, pain, tenderness, or unusual warmth in one of your legs or arms
  • Sudden shortness of breath or trouble breathing
  • Sharp chest pain that may get worse when you take a deep breath
  • A rapid heart rate or coughing up blood

Frequently Asked Questions

Why does lenalidomide cause blood clots?
Lenalidomide makes your blood platelets more responsive and alters chemical signals in your bloodstream. This risk is especially high when it is combined with corticosteroids like dexamethasone, creating a state where your blood clots too easily.
Do I need a prescription blood thinner or just aspirin with Revlimid?
Your doctor will calculate your personal clot risk using a specialized scoring system like the IMPEDE VTE or SAVED score. Lower-risk patients often only need a daily aspirin, while higher-risk patients may require a prescription blood thinner or daily injection.
When is the risk of getting a blood clot highest while taking lenalidomide?
The risk of developing a blood clot is highest during the first six months of your lenalidomide treatment. However, you should never stop taking your preventative blood thinner without consulting your care team, as many patients need to stay on it for their entire treatment.
What are the warning signs of a blood clot I should watch for?
Seek immediate medical attention if you experience leg or arm swelling, sudden shortness of breath, sharp chest pain when breathing, a rapid heart rate, or coughing up blood. These are warning signs of a serious blood clot.

Questions for Your Doctor

  • • What was my IMPEDE VTE or SAVED score, and how did that influence the preventative medication you chose for me?
  • • How will my kidney function be monitored to ensure my current blood thinner dosage remains safe and effective?
  • • Are there specific signs of internal bleeding I should watch out for now that I am taking this blood thinner?
  • • At what point in my treatment plan will we re-evaluate my need for a blood thinner or adjust the dosage?

Questions for You

  • • Have I ever had a blood clot (like a DVT or PE) in the past, or has anyone in my immediate family had one?
  • • Are there times in my daily routine where I sit for long periods, and how can I incorporate more movement to keep my blood flowing?
  • • Do I have any history of stomach ulcers or other bleeding conditions that I need to make sure my cancer care team knows about?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy.

    Covut F, Sanfilippo KM

    Hematology. American Society of Hematology. Education Program 2022; (2022(1)):363-367 doi:10.1182/hematology.2022000414.

    PMID: 36485142
  2. 2

    Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.

    Maharaj S, Chang S, Seegobin K, et al.

    Expert review of anticancer therapy 2017; (17(7)):585-591 doi:10.1080/14737140.2017.1330153.

    PMID: 28508703
  3. 3

    Venous thromboembolism in multiple myeloma is associated with increased mortality.

    Schoen MW, Carson KR, Luo S, et al.

    Research and practice in thrombosis and haemostasis 2020; (4(7)):1203-1210 doi:10.1002/rth2.12411.

    PMID: 33134785
  4. 4

    Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.

    Chalayer E, Talbot A, Frenzel L, et al.

    Journal of thrombosis and haemostasis : JTH 2022; (20(8)):1859-1867 doi:10.1111/jth.15758.

    PMID: 35557490
  5. 5

    Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network.

    Gerotziafas G, Fotiou D, Nijhof I, et al.

    HemaSphere 2025; (9(8)):e70177 doi:10.1002/hem3.70177.

    PMID: 40880878
  6. 6

    Multiple myeloma and its treatment contribute to increased platelet reactivity.

    Mitchell JL, Khan D, Rana RH, et al.

    Platelets 2023; (34(1)):2264940 doi:10.1080/09537104.2023.2264940.

    PMID: 37822056
  7. 7

    Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma.

    Sánchez Prieto I, Gutiérrez Jomarrón I, Martínez Vázquez C, et al.

    Journal of thrombosis and thrombolysis 2024; (57(6)):984-995 doi:10.1007/s11239-024-02977-0.

    PMID: 38676874
  8. 8

    Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group.

    Frenzel L, Decaux O, Macro M, et al.

    Thrombosis research 2024; (233()):153-164 doi:10.1016/j.thromres.2023.11.021.

    PMID: 38064842
  9. 9

    Optimising cardiovascular care of patients with multiple myeloma.

    Fontes Oliveira M, Naaktgeboren WR, Hua A, et al.

    Heart (British Cardiac Society) 2021; (107(22)):1774-1782 doi:10.1136/heartjnl-2020-318748.

    PMID: 33820757
  10. 10

    Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.

    Palmaro A, Rougé-Bugat ME, Gauthier M, et al.

    Pharmacoepidemiology and drug safety 2017; (26(5)):578-586 doi:10.1002/pds.4180.

    PMID: 28198064
  11. 11

    Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel.

    De Stefano V, Larocca A, Carpenedo M, et al.

    Haematologica 2022; (107(11)):2536-2547 doi:10.3324/haematol.2022.280893.

    PMID: 35861017
  12. 12

    Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.

    Sanfilippo KM, Luo S, Wang TF, et al.

    American journal of hematology 2019; (94(11)):1176-1184 doi:10.1002/ajh.25603.

    PMID: 31379000
  13. 13

    Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma.

    Li A, Wu Q, Luo S, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2019; (17(7)):840-847.

    PMID: 31319391
  14. 14

    Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines.

    Charalampous C, Shah D, Kumar S, Chakraborty R

    Annals of hematology 2024; (103(10)):3881-3888 doi:10.1007/s00277-024-05733-9.

    PMID: 38630132
  15. 15

    Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?

    Lapietra G, Serrao A, Fazio F, et al.

    Journal of thrombosis and thrombolysis 2021; (52(2)):584-589 doi:10.1007/s11239-020-02354-7.

    PMID: 33417149
  16. 16

    Study on Risk Factors and Treatment Strategies for Deep Vein Thrombosis in Patients with Multiple Myeloma.

    Guo Y, Yan L, Yang X, et al.

    Cancer management and research 2025; (17()):1667-1677 doi:10.2147/CMAR.S533589.

    PMID: 40837328
  17. 17

    Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial.

    Chalayer E, Frere C, Daguenet E, et al.

    Journal of thrombosis and haemostasis : JTH 2025; (23(10)):3220-3230 doi:10.1016/j.jtha.2025.06.012.

    PMID: 40523501
  18. 18

    Lenalidomide Promotes Thrombosis Formation, but Does Not Affect Platelet Activation in Multiple Myeloma.

    Li P, Xu B, Xu J, et al.

    International journal of molecular sciences 2023; (24(18)) doi:10.3390/ijms241814097.

    PMID: 37762399
  19. 19

    Bleeding risk from anticoagulant thromboprophylaxis in patients with multiple myeloma: a MarketScan analysis.

    Adrianzen-Herrera D, Giorgio K, Walker RF, et al.

    Research and practice in thrombosis and haemostasis 2024; (8(4)):102418 doi:10.1016/j.rpth.2024.102418.

    PMID: 38798793

This page explains the blood clot risks associated with lenalidomide for educational purposes only. Always consult your oncology team before changing or stopping your prescribed blood thinner or aspirin regimen.

Stay up to date

Get notified when new research about Multiple Myeloma is published.

No spam. Unsubscribe anytime.